The impact of new weight loss treatments is being felt well beyond the health-care industry . During the second quarter, which beat expectations , shoppers were still focused on health and wellness, CEO Doug McMillon said Thursday. Some companies already bar weight loss medications from their insurance plans to keep costs down. Executives said it was tied to an increase in specialty drug use for weight loss and diabetes. Eli Lilly's Mounjaro hasn't yet been approved for weight loss, though some people are taking it off label for that reason.

---

Persons: Eli Lilly, Joe Scalzo, Scalzo, Atkins, Regeneron, George Yancopoulos, Doug McMillon, WMT, Kroger, Paul Sarvadi, Eli Lilly's Mounjaro, Stephan Tata, Tata hedged, Tata Organizations: Analysts, Novo Nordisk, Co, Simply, Atkins, Walmart, WMT KR, Kroger, Cardinal Health, Drug Administration, Tata Locations: U.S